Literature DB >> 22457529

APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.

Marcel Ooms1, Aikaterini Krikoni, Andrea K Kress, Viviana Simon, Carsten Münk.   

Abstract

The human APOBEC3 family consists of seven cytidine deaminases (A3A to A3H), some of which display potent antiretroviral activity against HIV-1 and other retroviruses. Studies that analyzed the effect of A3G on human T-lymphotropic virus type 1 (HTLV-1) infectivity resulted in conflicting findings, and our knowledge of HTLV-1 restriction by other A3 proteins remains limited. Since HTLV-1, much like HIV, targets CD4(+) T cells, we hypothesized that A3 proteins other than A3G restrict HTLV-1. All seven human A3 proteins were tested in HTLV-1 reporter and HIV-1 infectivity assays. We show that A3A, A3B, and A3H haplotype 2 (A3H hapII) acted as potent inhibitors of HTLV-1. Wild-type HIV-1, in contrast, was restricted by A3B and A3H hapII, but not by A3A. Catalytic site mutants of A3A, A3B, and A3H hapII showed that A3A and A3B restriction of HTLV-1 required deaminase activity. However, A3H hapII acted in a deaminase-independent manner when restricting HTLV-1, while requiring deaminase activity for HIV-1 restriction. We also analyzed A3 editing of HTLV-1 in five T-cell lines obtained from HTLV-1-infected patients. These cell lines contained extensively edited HTLV-1 sequences with G-to-A mutations in dinucleotide contexts suggestive of APOBEC3 mutagenesis. Comparison of the A3-induced mutations from reporter cells and the patient-derived cell lines indicate that A3G but also other A3 members, possibly A3A and A3B, affect HTLV-1 in vivo. Taken together, our data indicate that HTLV-1 is a likely target for multiple A3 proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457529      PMCID: PMC3372211          DOI: 10.1128/JVI.06570-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  93 in total

Review 1.  Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection.

Authors:  A Gessain
Journal:  J Neurovirol       Date:  1996-10       Impact factor: 2.643

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes.

Authors:  J S Gibbs; D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

4.  Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia.

Authors:  B J Poiesz; F W Ruscetti; M S Reitz; V S Kalyanaraman; R C Gallo
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

5.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes.

Authors:  J P Vartanian; A Meyerhans; B Asjö; S Wain-Hobson
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Antibody responses to the env epitopes of human T-lymphotropic virus type I in rhesus macaques' naturally infected with simian T-lymphotropic virus type I.

Authors:  D L Rudolph; J Yee; T Palker; J E Coligan; R B Lal
Journal:  Res Virol       Date:  1993 May-Jun

7.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

Review 8.  An HTLV-I/II vaccine: from animal models to clinical trials?

Authors:  G de Thé; M Kazanji
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996

9.  Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

Authors:  H H Lee; S H Weiss; L S Brown; D Mildvan; V Shorty; L Saravolatz; A Chu; H M Ginzburg; N Markowitz; D C Des Jarlais
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

10.  Phylogenetic associations of human and simian T-cell leukemia/lymphotropic virus type I strains: evidence for interspecies transmission.

Authors:  I J Koralnik; E Boeri; W C Saxinger; A L Monico; J Fullen; A Gessain; H G Guo; R C Gallo; P Markham; V Kalyanaraman
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  61 in total

1.  In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.

Authors:  Yuki Nakaya; Spyridon Stavrou; Kristin Blouch; Peter Tattersall; Susan R Ross
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

2.  APOBEC3A Is Upregulated by Human Cytomegalovirus (HCMV) in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector.

Authors:  Yiska Weisblum; Esther Oiknine-Djian; Zichria Zakay-Rones; Olesya Vorontsov; Ronit Haimov-Kochman; Yuval Nevo; David Stockheim; Simcha Yagel; Amos Panet; Dana G Wolf
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 3.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

4.  Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic.

Authors:  Allison M Land; Emily K Law; Michael A Carpenter; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

Review 5.  Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.

Authors:  Yaqiong Wang; Kimberly Schmitt; Kejun Guo; Mario L Santiago; Edward B Stephens
Journal:  J Gen Virol       Date:  2015-10-20       Impact factor: 3.891

6.  Cellular HIV-1 inhibition by truncated old world primate APOBEC3A proteins lacking a complete deaminase domain.

Authors:  Miki Katuwal; Yaqiong Wang; Kimberly Schmitt; Kejun Guo; Kalani Halemano; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2014-09-28       Impact factor: 3.616

Review 7.  The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.

Authors:  Abby M Green; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2019-09-13

8.  Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity.

Authors:  In-Ja L Byeon; Chang-Hyeock Byeon; Tiyun Wu; Mithun Mitra; Dustin Singer; Judith G Levin; Angela M Gronenborn
Journal:  Biochemistry       Date:  2016-05-19       Impact factor: 3.162

9.  Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes.

Authors:  Shraddha Sharma; Santosh K Patnaik; Zeynep Kemer; Bora E Baysal
Journal:  RNA Biol       Date:  2016-05-05       Impact factor: 4.652

10.  Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.

Authors:  Spyridon Stavrou; Takayuki Nitta; Swathi Kotla; Dat Ha; Kunio Nagashima; Alan R Rein; Hung Fan; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.